The multikinase inhibitor RXDX-105 is effective against neuroblastomain vitroandin vivo
Authors:
Open Access
- 29 October 2019
- journal article
- Published by Impact Journals, LLC in Oncotarget
- Vol. 10 (59) , 6323-6333
Abstract
Oncotarget | https://doi.org/10.18632/oncotarget.27259 Sean M. Flynn, Jacqueline Lesperance, Andrew Macias, Nikki Phanhthilath, Megan Rose Paul, Jong Wook Kim, Pablo Tamayo, Peter E. ZageKeywords
This publication has 36 references indexed in Scilit:
- CEP-32496: A Novel Orally Active BRAFV600E Inhibitor with Selective Cellular and In Vivo Antitumor ActivityMolecular Cancer Therapeutics, 2012
- Oncogene Mutation Profiling of Pediatric Solid Tumors Reveals Significant Subsets of Embryonal Rhabdomyosarcoma and Neuroblastoma with Mutated Genes in Growth Signaling PathwaysClinical Cancer Research, 2012
- Clinical and Biologic Features Predictive of Survival After Relapse of Neuroblastoma: A Report From the International Neuroblastoma Risk Group ProjectJournal of Clinical Oncology, 2011
- NeuroblastomaAdvances in Pediatrics, 2011
- A novel therapeutic combination for neuroblastomaCancer, 2010
- Long-Term Results for Children With High-Risk Neuroblastoma Treated on a Randomized Trial of Myeloablative Therapy Followed by 13-cis-Retinoic Acid: A Children's Oncology Group StudyJournal of Clinical Oncology, 2009
- Hyperactive Ras in developmental disorders and cancerNature Reviews Cancer, 2007
- Mechanisms of Disease: oncogene addiction—a rationale for molecular targeting in cancer therapyNature Clinical Practice Oncology, 2006
- Addiction to Oncogenes--the Achilles Heal of CancerScience, 2002
- Expression of the ret proto‐oncogene product in human normal and neoplastic tissues of neural crest originThe Journal of Pathology, 1994